SCHEMBL3713655

SCHEMBL3713655

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccc(Cl)c(F)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.60
ALOX15 P16050 5/20 0.55
LMNA P02545 1/20 0.55
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
HPGD P15428 3/20 0.53
HTT P42858 2/20 0.53
ALDH1A1 P00352 3/20 0.53
POLB P06746 1/20 0.53
KDM4E B2RXH2 3/20 0.53
FPR1 P21462 3/20 0.52
GAA P10253 4/20 0.51
HSD17B10 Q99714 1/20 0.51
TSHR P16473 3/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705034 0.93 USP7 (0.59) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3716653 0.90 USP7 (0.70) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3710756 0.85 USP7 (0.63) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3705035 0.82 KDM4E (0.66) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3706706 0.81 MEN1 (0.60) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3707576 0.81 KDM4E (0.64) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL16904821 0.81 KDM4E (0.64) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3705340 0.80 MEN1 (0.78) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3713778 0.80 KDM4E (0.63) USP7ALOX15LMNAMEN1KMT2A
SCHEMBL3709475 0.79 KDM4E (0.59) USP7ALOX15LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed